AbbVie’s Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and Welfare (MHLW) Approval to Treat Plaque Psoriasis, Generalized Pustular Psoriasis, Erythrodermic Psoriasis and Psoriatic Arthritis in Adults

Shots:

• The approval is based on P-II & P-III sustaIMM, ultIMMa-1 and IMMspire study results assessing Skyrizi in Japanese patients with plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis & active psoriatic arthritis
• The study resulted in safe and effective results and has capabilities to improve the signs of these chronic immune-mediated diseases
• Skyrizi (risankizumab) is a humanized immunoglobulin G1 (IgG1) mAb inhibiting IL-23 and has received a positive opinion from the EMA’s CHMP for moderate to severe plaque psoriasis in adult patients in Feb, 2019 and currently under review with the US FDA

Click here to read full press release/ article | Ref: AbbVie | Image: Imagenesmy